Close menu

April 4th, 2022 | 11:20 CEST

Millions with innovations: BioNTech, Meta Materials, Varta

  • Technology
  • Biotechnology
Photo credits:

When the long-forgotten solar company SolarWorld went public in 1999, n-tv ran commercials that, from today's perspective, looked rather amateurish. At that time, too, only a few private investors were initially convinced by the Company. Years later, SolarWorld was a success story - investors from the very beginning had become rich. Even though the Company filed for insolvency in the meantime and burned a lot of money - SolarWorld investors of the first hour are mostly still wealthy. We explain where innovations can develop blockbuster potential.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , Meta Materials Inc. | US59134N1046 , VARTA AG O.N. | DE000A0TGJ55

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech: The market says "yes" to mRNA

    The example of BioNTech shows that the rise of industry giants does not necessarily have to take decades. Apart from the vaccine of Moderna, the mRNA specialist from Mainz has brought to market what is probably the best vaccine against COVID-19. It ensured a net profit of a whopping EUR 10 billion in just one year. In terms of profit, BioNTech has gone from a startup to a major corporation in just three years. Since the Company is well-positioned around mRNA technology and, unlike in the past, no longer has to go door-to-door to raise funds, the stock could also be promising.

    But between last summer and the beginning of March, the stock only went down. Most recently, BioNTech has been able to free itself a little and is preparing to leave the downward trend. In the medium term, the stock should overcome the EUR 200 mark to get back into more positive waters. However, the extent to which the share is still good for the multiplication that investors are hoping for remains to be seen. In the meantime, a lot seems to have been priced in around BioNTech and the mRNA technology.

    Meta Materials: More than a second Gamestop share

    Last summer, the market had also priced in a lot for Meta Materials: At its peak, the stock reached a whopping USD 21.76 on the US stock exchange Nasdaq. On a daily closing basis, there is still a high for the year of 7.49. Today, the stock is trading at USD 1.58. What has happened? Not much. Meta Materials wants to make so-called metamaterials presentable and enable industrial production at competitive prices. Metamaterials are artificial substances with properties that do not physically occur in nature. Concrete applications include transparent coatings that take on the function of antennas or coatings that refract light in such a way that objects become invisible because the light is deflected around them. What sounds like science fiction is reality - just not yet producible at such low cost. Meta Materials is confident, however, that it will soon be able to address this problem effectively.

    Until then, the Company is suffering the fate of many growth companies. The Company recently reported a loss and weak sales figures, and the market acknowledged the Company's news with share price losses. But the Company's field of activity is unique and offers the potential to become the "next big thing". The magazine "Spektrum der Wissenschaft" has already dedicated an entire topic page to metamaterials. Anyone interested in future technology can read up on it. Investors must decide for themselves whether the share has a future - the value does not appear expensive at present after the price losses.

    Varta: Rather conservative

    If you want to score with innovations, you should have a lot of know-how in your industry. And that is exactly the case for the battery manufacturer Varta. The Company scores with button cells for hearing aids and headphones and is also taking off with batteries for e-cars. Last week, Varta exceeded its guidance and analysts' expectations with its business figures for 2021. In 2022, sales are expected to increase from around EUR 900 million to EUR 950 million. From 2023, sales of rechargeable batteries for e-cars are to be the new revenue driver. However, the fantasy around e-cars is now out at Varta - the advance praise around the share was too great last year, and the battery perspective is too far away. It is also not clear whether Varta will truly be able to outdo the competition from around the world.

    While Varta is a laggard in the e-car battery space, Meta Materials is entering completely new territory with its approach. The perspective of the Nasdaq stock is thus similar to BioNTech at the beginning of the pandemic. Only the catalyst that will help Meta Materials achieve a breakthrough is currently still missing. However, many innovations are conceivable for Meta Materials in the areas of data glasses, smart displays, the energy transition, and telecommunications.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on May 23rd, 2024 | 08:45 CEST

    Defence Therapeutics, Super Micro Computer, Evotec: Fresh patents, revenue explosion, and cyberattacks - These companies overcome all hurdles

    • Biotechnology
    • Pharma
    • AI

    Medicine and research go hand in hand. The Canadian biotech company Defence Therapeutics is expanding its patent protection for its platform technology in order to further advance the development of drugs, vaccines, and active ingredients. Data collection and analysis require intelligent solutions such as those from Super Micro Computer. With an incredible 200% increase in revenue, the US company from Silicon Valley is surfing the digital wave of success. Will they continue to rise? Meanwhile, Evotec is grappling with the darker side of digitalization. Due to a cyberattack, the life sciences company is withdrawing from an otherwise lucrative segment. We provide the details.


    Commented by Stefan Feulner on May 22nd, 2024 | 07:00 CEST

    BioNTech, Cardiol Therapeutics, Morphosys - On the verge of a breakout

    • Biotechnology
    • Pharma

    Compared to the broader indices, DAX and Dow Jones, which have already reached new all-time highs, the Nasdaq Biotech Index is currently lagging. The sector index is still around 23% below its peak from August 2021. Nevertheless, the sector is on the move. In addition to takeovers, which have increased dramatically in 2024, many companies have important study results in the pipeline that could kick-start a rally.


    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.